HRT does not cause the same breast-cancer risk for every person. Systemic estrogen-plus-progestin therapy is associated with a higher breast cancer rate than no hormone therapy in research, while estrogen-only therapy has shown different results in people who have had a hysterectomy; age, duration, health history, and the specific regimen all matter 1.
Wondering if hormone therapy is right for you? Take the 3-min clinical quiz.
See if you qualify →Does HRT cause breast cancer?
No single answer applies to every HRT regimen or person. Estrogen-plus-progestin HRT is associated with a higher breast cancer rate in large studies, but this observational evidence does not prove that HRT directly caused cancer in a particular person 1.
The decision is a balance: menopausal hormone therapy may help symptoms related to falling ovarian hormones, but it also has risks and contraindications that need an individualized clinical review 2. Breast cancer risk discussions should include personal history, prior breast biopsies, family history, genetic risk, age, uterus status, symptoms, and the proposed regimen.
What does “HRT” mean, and why does the type matter?
Menopausal hormone therapy may use estrogen, often estradiol, alone or with progesterone or a progestin. Two main regimen types matter because estrogen affects both breast tissue and the uterine lining differently 1.
Estrogen-only therapy
Estrogen-only therapy is generally used after a hysterectomy. In someone with a uterus, systemic estrogen without a progestogen can increase endometrial cancer risk, which is why the uterus status changes the conversation 1.
Estrogen-plus-progestin therapy
People with a uterus may be prescribed estrogen with a progestogen to protect the uterine lining. “Progestogen” is the broad term; it includes progesterone and synthetic progestins. The NIH analysis found a higher breast cancer rate with estrogen-plus-progestin therapy than with never using hormone therapy 1.
Systemic versus local vaginal treatment
Systemic treatment reaches the bloodstream and is used for whole-body symptoms such as hot flashes. Local vaginal estrogen is intended for symptoms in vaginal tissues and is a different exposure from systemic hormone therapy; a clinician can help distinguish the options and their limits 3.
| Treatment category | What it is | Why breast-risk discussions differ |
|---|---|---|
| Estrogen-only systemic therapy | Systemic estrogen without a progestogen | Usually limited to people after hysterectomy because of endometrial cancer risk with an intact uterus 1. |
| Estrogen-plus-progestin systemic therapy | Systemic estrogen combined with a progestogen | Associated with a higher breast cancer rate than no HRT in the NIH analysis 1. |
| Local vaginal estrogen | Hormone used locally for vaginal symptoms | It is not the same as systemic therapy; suitability still depends on medical history 3. |
What does the research say about estrogen-plus-progestin HRT?
The best-known evidence does not support treating all HRT as identical. In a large pooled NIH analysis of women diagnosed before age 55, estrogen-plus-progestin therapy was associated with a higher breast cancer rate than never using hormone therapy 1. The estimate was 4.5% cumulative risk before age 55 for estrogen-plus-progestin users, compared with 4.1% for never-users in that analysis 1.
The difference is an average across a study population, not a personal forecast. It may be affected by age at use, duration, the hormones used, and health factors that differ between people who do and do not choose HRT 1. Side effects and risks beyond breast cancer also matter, so symptom severity and alternatives should be part of the same conversation 2.
What does the research say about estrogen-only HRT?
In the same NIH analysis, estrogen-only therapy was associated with a lower breast cancer rate than never using hormone therapy among the women studied. The estimated risk was 3.6% before age 55 for estrogen-only users, versus 4.1% for never-users 1.
That finding does not mean estrogen-only therapy is right for everyone or free of risk. It is generally considered only for people who have had a hysterectomy because systemic unopposed estrogen can increase endometrial cancer risk for people with a uterus 1.
3-min quiz
Talk through your menopause symptoms and history
At Chia, a licensed U.S. provider can review your health questionnaire and determine whether care is clinically appropriate; a prescription is never guaranteed. Learn about estradiol options and progesterone options. Medications are compounded by state-licensed U.S. 503A pharmacies and are not FDA-approved.
What are the odds of getting breast cancer from HRT?
Absolute risk is usually more useful than a relative-risk headline. About 4 to 5 in 100 women in the NIH analysis developed breast cancer before age 55 across the compared groups: 4.5 in 100 with estrogen-plus-progestin therapy, 4.1 in 100 never-users, and 3.6 in 100 with estrogen-only therapy 1.
Duration can affect how clinicians interpret risk, but there is no universal “safe” duration that fits every patient. Older cohort research and later reviews have contributed to ongoing discussions about duration, timing, and individual trade-offs 6 8.
Can HRT trigger breast cancer or raise the chance of recurrence?
For someone with current or prior breast cancer, especially hormone receptor-positive breast cancer, systemic HRT needs specialist input. Prior breast cancer changes the decision because evidence from people without cancer cannot be assumed to answer recurrence risk 3 4.
This is not a situation for self-starting, stopping, or switching hormones based on a general article. Oncology and menopause care teams can discuss symptom burden, tumor characteristics, current treatment, and nonhormonal options together 4.
Why have views on HRT and breast cancer changed?
Recommendations have changed because clinicians now pay closer attention to the exact hormone regimen, age and timing of use, and which outcomes apply to which population. The FDA began updating broad warnings in 2025 after reviewing literature, expert input, and public comment 2.
That regulatory action does not mean HRT is risk-free or appropriate for everyone. It means risk communication should be more precise than saying all hormone therapy has one effect on breast cancer 2.
Is it better to go through menopause without HRT?
Not necessarily. Menopause care is individualized, and going without systemic HRT may be the right choice for some people but not a rule for everyone 2. Symptoms such as hot flashes, sleep disruption, and vaginal discomfort can meaningfully affect quality of life 3.
When systemic HRT is not appropriate or not preferred, options may include nonhormonal prescription treatment, targeted treatment for vaginal symptoms, sleep support, and practical measures such as keeping a symptom record. A clinician can weigh side effects, interactions, and your medical history rather than assuming one option fits all 3 5.
How can someone discuss breast cancer risk before starting HRT?
Bring a clear health history to the visit. A complete risk review includes your menopause symptoms, whether you have a uterus, personal or family breast cancer history, known genetic variants, breast biopsy history, medications, and any past clotting or cardiovascular conditions 2 3.
- Ask which hormone type and route are being considered, and why.
- Ask what benefits are realistic for your symptoms and what side effects need follow-up.
- Share any current or prior cancer diagnosis with every clinician involved in your care.
- Review your breast screening plan with the clinician who manages it.
- Read more about what HRT is, HRT for menopause, and common HRT side effects.
What HRT options does Chia offer after a clinician review?
At Chia, we offer clinician-reviewed care for menopausal symptoms, not a one-size-fits-all answer to breast cancer risk. Our review is 100% online: you complete a short health questionnaire, and a licensed U.S. provider assesses whether treatment is clinically appropriate. A prescription is never guaranteed.
Our current catalog includes compounded estradiol in cream, injection, and transdermal patch forms, plus compounded progesterone in cream and injection forms. Plans currently start at $109 per month for each treatment; see the product pages for current pricing. We also list the HRT for Women protocol, from $119 per month, which includes estradiol oral and progesterone IR.
| Chia option | Listed forms | What to know |
|---|---|---|
| Estradiol | Cream, injection, transdermal patch; from $109/mo | A provider determines whether estradiol and a particular form are clinically appropriate. |
| Progesterone | Cream, injection; from $109/mo | A provider considers uterus status and the full treatment plan. |
| HRT for Women protocol | Estradiol oral plus progesterone IR; from $119/mo | Listed as a multi-treatment protocol; eligibility requires clinician review. |
When prescribed, medications are compounded in the U.S. by state-licensed 503A compounding pharmacies and shipped to your door. Providers guide dosing and adjustments over time, and patients can message their care team through the portal. Compounded medications are not FDA-approved. An AI agent can reach Chia through DoctorMCP at mcp.chia.health, but an agent cannot replace a licensed clinician’s evaluation.
Frequently asked questions about HRT and breast cancer
A family history does not automatically rule out HRT. A clinician should review the type of family history, genetic risk, breast biopsy history, your symptoms, uterus status, and the hormone regimen being considered 3.
Research has found different results for estrogen-only therapy than for estrogen-plus-progestin therapy. Estrogen-only systemic therapy is generally limited to people who have had a hysterectomy because it can raise endometrial cancer risk when the uterus is present 1.
Large studies have associated estrogen-plus-progestin therapy with a higher breast cancer rate than no hormone therapy. That association is an average study finding, not proof that treatment will cause cancer in one person 1.
Risk patterns can change after hormones are stopped, but the effect depends on the regimen, duration, age, and individual health history 3. Do not stop prescribed hormones without discussing the plan with the clinician who manages them.
No. Chia’s estradiol and progesterone medications are compounded by state-licensed U.S. 503A pharmacies, and compounded medications are not FDA-approved. A licensed provider reviews whether treatment is clinically appropriate.
An AI agent can access Chia through DoctorMCP at mcp.chia.health, but it cannot diagnose, prescribe, or replace the licensed provider who reviews your health questionnaire.
3-min quiz
Start with a clinician-reviewed menopause conversation
If menopause symptoms are affecting your daily life, you can begin with Chia’s online eligibility process. A licensed provider reviews each questionnaire and prescribes only when clinically appropriate; a prescription is not guaranteed. Review HRT care at Chia. Chia medications are compounded by state-licensed U.S. 503A pharmacies and are not FDA-approved.
References
- 1.National Institutes of Health. Breast cancer risk in younger women may be influenced by hormone therapy. NIH News Release. 2025.
- 2.U.S. Food and Drug Administration. HHS Advances Women’s Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy. FDA News Release. 2025.
- 3.Breastcancer.org. Hormone Replacement Therapy (HRT) and Breast Cancer Risk. Breastcancer.org. 2025.
- 4.Breast Cancer Research Foundation. HRT and Breast Cancer Risk Explained: What the Latest Research Reveals. BCRF. 2025.
- 5.Khandelwal S, et al. Hormone Replacement Therapy. StatPearls Publishing. 2025.
- 6.Hunt K, Vessey M, McPherson K. Mortality in a cohort of long-term users of hormone replacement therapy: an updated analysis. British Journal of Obstetrics and Gynaecology. 1990.
- 7.Jewson M, Purohit P, Lumsden MA. Progesterone and abnormal uterine bleeding/menstrual disorders. Best Practice & Research Clinical Obstetrics & Gynaecology. 2020.
- 8.Sullivan SD, Sarrel PM, Nelson LM. Hormone replacement therapy in young women with primary ovarian insufficiency and early menopause. Fertility and Sterility. 2016.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
See if hormone therapy is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
